http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 02 Mar 2026 07:16:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++COMPUGEN+LTD++++++++++++++For%3A+Dec+31/26086901.html si-local-file:///var/storage/secattach/20260302/26086901.html http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++COMPUGEN+LTD++++++++++++++For%3A+Dec+31/26086901.html Mon, 02 Mar 2026 07:16:00 -0500 CGEN O.00653212 http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++COMPUGEN+LTD++++++++++++++For%3A+Dec+31/26086901.html si-local-file:///var/storage/secattach/20260302/26086901.html http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++COMPUGEN+LTD++++++++++++++For%3A+Dec+31/26086901.html Mon, 02 Mar 2026 07:16:00 -0500 CGEN O.00653212 http://www.streetinsider.com/Earnings/Compugen+%28CGEN%29+Tops+Q4+EPS+by+68c/26086852.html <p>Compugen (NASDAQ: CGEN) reported Q4 EPS of $0.60, $0.68 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $67.33 million.</p><p>For earnings history and earnings-related data on Compugen (CGEN) <a href="http://www.streetinsider.com/ec_earnings.php?q=CGEN">click here</a>.</p> http://www.streetinsider.com/Earnings/Compugen+%28CGEN%29+Tops+Q4+EPS+by+68c/26086852.html Mon, 02 Mar 2026 07:06:13 -0500 CGEN http://www.streetinsider.com/Press+Releases/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html <div class="xn-content"> <ul type="disc"><li>Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029</li><li>Enhanced leadership team with Dr. <person>Eran Ophir</person> appointed President and CEO and Dr. <person value="APIN:4223132347">Anat Cohen-Dayag</person> transitioned to Executive Chair</li><li>Advanced clinical execution, including initiation of trials for wholly owned COM701 (MAIA-ovarian) and Gilead partnered GS-0321 and expansion of the Company's global clinical trial footprint</li><li>Presented clinical updates for COM701 and GS-0321 at ESMO and SITC 2025, respectively</li><li>On track to have MAIA-ovarian interim analysis in Q1 2027</li><li>Partner AstraZeneca reported promising Phase 2 rilvegostomig data at ESMO 2025, with http://www.streetinsider.com/Press+Releases/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html Mon, 02 Mar 2026 07:00:00 -0500 A.08181543 CGEN CGEN CW9 CW9 O.00653212 O.34295762 http://www.streetinsider.com/Press+Releases/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html <div class="xn-content"> <ul type="disc"><li>Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029</li><li>Enhanced leadership team with Dr. <person>Eran Ophir</person> appointed President and CEO and Dr. <person value="APIN:4223132347">Anat Cohen-Dayag</person> transitioned to Executive Chair</li><li>Advanced clinical execution, including initiation of trials for wholly owned COM701 (MAIA-ovarian) and Gilead partnered GS-0321 and expansion of the Company's global clinical trial footprint</li><li>Presented clinical updates for COM701 and GS-0321 at ESMO and SITC 2025, respectively</li><li>On track to have MAIA-ovarian interim analysis in Q1 2027</li><li>Partner AstraZeneca reported promising Phase 2 rilvegostomig data at ESMO 2025, with http://www.streetinsider.com/Press+Releases/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html Mon, 02 Mar 2026 07:00:00 -0500 A.08181543 CGEN CGEN CW9 CW9 O.00653212 O.34295762 http://www.streetinsider.com/Press+Releases/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html <div class="xn-content"> <ul type="disc"><li>Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029</li><li>Enhanced leadership team with Dr. <person>Eran Ophir</person> appointed President and CEO and Dr. <person value="APIN:4223132347">Anat Cohen-Dayag</person> transitioned to Executive Chair</li><li>Advanced clinical execution, including initiation of trials for wholly owned COM701 (MAIA-ovarian) and Gilead partnered GS-0321 and expansion of the Company's global clinical trial footprint</li><li>Presented clinical updates for COM701 and GS-0321 at ESMO and SITC 2025, respectively</li><li>On track to have MAIA-ovarian interim analysis in Q1 2027</li><li>Partner AstraZeneca reported promising Phase 2 rilvegostomig data at ESMO 2025, with http://www.streetinsider.com/Press+Releases/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html Mon, 02 Mar 2026 07:00:00 -0500 A.08181543 CGEN CGEN CW9 CW9 O.00653212 O.34295762 http://www.streetinsider.com/Press+Releases/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html <div class="xn-content"> <ul type="disc"><li>Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029</li><li>Enhanced leadership team with Dr. <person>Eran Ophir</person> appointed President and CEO and Dr. <person value="APIN:4223132347">Anat Cohen-Dayag</person> transitioned to Executive Chair</li><li>Advanced clinical execution, including initiation of trials for wholly owned COM701 (MAIA-ovarian) and Gilead partnered GS-0321 and expansion of the Company's global clinical trial footprint</li><li>Presented clinical updates for COM701 and GS-0321 at ESMO and SITC 2025, respectively</li><li>On track to have MAIA-ovarian interim analysis in Q1 2027</li><li>Partner AstraZeneca reported promising Phase 2 rilvegostomig data at ESMO 2025, with http://www.streetinsider.com/Press+Releases/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html Mon, 02 Mar 2026 07:00:00 -0500 A.08181543 CGEN CGEN CW9 CW9 O.00653212 O.34295762 http://www.streetinsider.com/Press+Releases/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html <div class="xn-content"> <ul type="disc"><li>Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029</li><li>Enhanced leadership team with Dr. <person>Eran Ophir</person> appointed President and CEO and Dr. <person value="APIN:4223132347">Anat Cohen-Dayag</person> transitioned to Executive Chair</li><li>Advanced clinical execution, including initiation of trials for wholly owned COM701 (MAIA-ovarian) and Gilead partnered GS-0321 and expansion of the Company's global clinical trial footprint</li><li>Presented clinical updates for COM701 and GS-0321 at ESMO and SITC 2025, respectively</li><li>On track to have MAIA-ovarian interim analysis in Q1 2027</li><li>Partner AstraZeneca reported promising Phase 2 rilvegostomig data at ESMO 2025, with http://www.streetinsider.com/Press+Releases/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html Mon, 02 Mar 2026 07:00:00 -0500 A.08181543 CGEN CGEN CW9 CW9 O.00653212 O.34295762 http://www.streetinsider.com/Press+Releases/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html <div class="xn-content"> <ul type="disc"><li>Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029</li><li>Enhanced leadership team with Dr. <person>Eran Ophir</person> appointed President and CEO and Dr. <person value="APIN:4223132347">Anat Cohen-Dayag</person> transitioned to Executive Chair</li><li>Advanced clinical execution, including initiation of trials for wholly owned COM701 (MAIA-ovarian) and Gilead partnered GS-0321 and expansion of the Company's global clinical trial footprint</li><li>Presented clinical updates for COM701 and GS-0321 at ESMO and SITC 2025, respectively</li><li>On track to have MAIA-ovarian interim analysis in Q1 2027</li><li>Partner AstraZeneca reported promising Phase 2 rilvegostomig data at ESMO 2025, with http://www.streetinsider.com/Press+Releases/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html Mon, 02 Mar 2026 07:00:00 -0500 A.08181543 CGEN CGEN CW9 CW9 O.00653212 O.34295762 http://www.streetinsider.com/Press+Releases/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html <div class="xn-content"> <ul type="disc"><li>Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029</li><li>Enhanced leadership team with Dr. <person>Eran Ophir</person> appointed President and CEO and Dr. <person value="APIN:4223132347">Anat Cohen-Dayag</person> transitioned to Executive Chair</li><li>Advanced clinical execution, including initiation of trials for wholly owned COM701 (MAIA-ovarian) and Gilead partnered GS-0321 and expansion of the Company's global clinical trial footprint</li><li>Presented clinical updates for COM701 and GS-0321 at ESMO and SITC 2025, respectively</li><li>On track to have MAIA-ovarian interim analysis in Q1 2027</li><li>Partner AstraZeneca reported promising Phase 2 rilvegostomig data at ESMO 2025, with http://www.streetinsider.com/Press+Releases/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html Mon, 02 Mar 2026 07:00:00 -0500 A.08181543 CGEN CGEN CW9 CW9 O.00653212 O.34295762 http://www.streetinsider.com/PRNewswire/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html <div class="xn-content"> <ul type="disc"><li>Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029</li><li>Enhanced leadership team with Dr. <person>Eran Ophir</person> appointed President and CEO and Dr. <person value="APIN:4223132347">Anat Cohen-Dayag</person> transitioned to Executive Chair</li><li>Advanced clinical execution, including initiation of trials for wholly owned COM701 (MAIA-ovarian) and Gilead partnered GS-0321 and expansion of the Company's global clinical trial footprint</li><li>Presented clinical updates for COM701 and GS-0321 at ESMO and SITC 2025, respectively</li><li>On track to have MAIA-ovarian interim analysis in Q1 2027</li><li>Partner AstraZeneca reported promising Phase 2 rilvegostomig data at ESMO 2025, with http://www.streetinsider.com/PRNewswire/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html Mon, 02 Mar 2026 07:00:00 -0500 A.08181543 CGEN CGEN CW9 CW9 O.00653212 O.34295762 http://www.streetinsider.com/PRNewswire/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html <div class="xn-content"> <ul type="disc"><li>Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029</li><li>Enhanced leadership team with Dr. <person>Eran Ophir</person> appointed President and CEO and Dr. <person value="APIN:4223132347">Anat Cohen-Dayag</person> transitioned to Executive Chair</li><li>Advanced clinical execution, including initiation of trials for wholly owned COM701 (MAIA-ovarian) and Gilead partnered GS-0321 and expansion of the Company's global clinical trial footprint</li><li>Presented clinical updates for COM701 and GS-0321 at ESMO and SITC 2025, respectively</li><li>On track to have MAIA-ovarian interim analysis in Q1 2027</li><li>Partner AstraZeneca reported promising Phase 2 rilvegostomig data at ESMO 2025, with http://www.streetinsider.com/PRNewswire/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html Mon, 02 Mar 2026 07:00:00 -0500 A.08181543 CGEN CGEN CW9 CW9 O.00653212 O.34295762 http://www.streetinsider.com/PRNewswire/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html <div class="xn-content"> <ul type="disc"><li>Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029</li><li>Enhanced leadership team with Dr. <person>Eran Ophir</person> appointed President and CEO and Dr. <person value="APIN:4223132347">Anat Cohen-Dayag</person> transitioned to Executive Chair</li><li>Advanced clinical execution, including initiation of trials for wholly owned COM701 (MAIA-ovarian) and Gilead partnered GS-0321 and expansion of the Company's global clinical trial footprint</li><li>Presented clinical updates for COM701 and GS-0321 at ESMO and SITC 2025, respectively</li><li>On track to have MAIA-ovarian interim analysis in Q1 2027</li><li>Partner AstraZeneca reported promising Phase 2 rilvegostomig data at ESMO 2025, with http://www.streetinsider.com/PRNewswire/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html Mon, 02 Mar 2026 07:00:00 -0500 A.08181543 CGEN CGEN CW9 CW9 O.00653212 O.34295762 http://www.streetinsider.com/PRNewswire/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html <div class="xn-content"> <ul type="disc"><li>Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029</li><li>Enhanced leadership team with Dr. <person>Eran Ophir</person> appointed President and CEO and Dr. <person value="APIN:4223132347">Anat Cohen-Dayag</person> transitioned to Executive Chair</li><li>Advanced clinical execution, including initiation of trials for wholly owned COM701 (MAIA-ovarian) and Gilead partnered GS-0321 and expansion of the Company's global clinical trial footprint</li><li>Presented clinical updates for COM701 and GS-0321 at ESMO and SITC 2025, respectively</li><li>On track to have MAIA-ovarian interim analysis in Q1 2027</li><li>Partner AstraZeneca reported promising Phase 2 rilvegostomig data at ESMO 2025, with http://www.streetinsider.com/PRNewswire/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html Mon, 02 Mar 2026 07:00:00 -0500 A.08181543 CGEN CGEN CW9 CW9 O.00653212 O.34295762 http://www.streetinsider.com/PRNewswire/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html <div class="xn-content"> <ul type="disc"><li>Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029</li><li>Enhanced leadership team with Dr. <person>Eran Ophir</person> appointed President and CEO and Dr. <person value="APIN:4223132347">Anat Cohen-Dayag</person> transitioned to Executive Chair</li><li>Advanced clinical execution, including initiation of trials for wholly owned COM701 (MAIA-ovarian) and Gilead partnered GS-0321 and expansion of the Company's global clinical trial footprint</li><li>Presented clinical updates for COM701 and GS-0321 at ESMO and SITC 2025, respectively</li><li>On track to have MAIA-ovarian interim analysis in Q1 2027</li><li>Partner AstraZeneca reported promising Phase 2 rilvegostomig data at ESMO 2025, with http://www.streetinsider.com/PRNewswire/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html Mon, 02 Mar 2026 07:00:00 -0500 A.08181543 CGEN CGEN CW9 CW9 O.00653212 O.34295762 http://www.streetinsider.com/PRNewswire/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html <div class="xn-content"> <ul type="disc"><li>Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029</li><li>Enhanced leadership team with Dr. <person>Eran Ophir</person> appointed President and CEO and Dr. <person value="APIN:4223132347">Anat Cohen-Dayag</person> transitioned to Executive Chair</li><li>Advanced clinical execution, including initiation of trials for wholly owned COM701 (MAIA-ovarian) and Gilead partnered GS-0321 and expansion of the Company's global clinical trial footprint</li><li>Presented clinical updates for COM701 and GS-0321 at ESMO and SITC 2025, respectively</li><li>On track to have MAIA-ovarian interim analysis in Q1 2027</li><li>Partner AstraZeneca reported promising Phase 2 rilvegostomig data at ESMO 2025, with http://www.streetinsider.com/PRNewswire/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html Mon, 02 Mar 2026 07:00:00 -0500 A.08181543 CGEN CGEN CW9 CW9 O.00653212 O.34295762 http://www.streetinsider.com/PRNewswire/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html <div class="xn-content"> <ul type="disc"><li>Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029</li><li>Enhanced leadership team with Dr. <person>Eran Ophir</person> appointed President and CEO and Dr. <person value="APIN:4223132347">Anat Cohen-Dayag</person> transitioned to Executive Chair</li><li>Advanced clinical execution, including initiation of trials for wholly owned COM701 (MAIA-ovarian) and Gilead partnered GS-0321 and expansion of the Company's global clinical trial footprint</li><li>Presented clinical updates for COM701 and GS-0321 at ESMO and SITC 2025, respectively</li><li>On track to have MAIA-ovarian interim analysis in Q1 2027</li><li>Partner AstraZeneca reported promising Phase 2 rilvegostomig data at ESMO 2025, with http://www.streetinsider.com/PRNewswire/Compugen+Reports+Fourth+Quarter+and+Full+Year+2025+Results/26086735.html Mon, 02 Mar 2026 07:00:00 -0500 A.08181543 CGEN CGEN CW9 CW9 O.00653212 O.34295762 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++COMPUGEN+LTD++++++++++++++For%3A+Mar+02/26086764.html si-local-file:///var/storage/secattach/20260302/26086764.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++COMPUGEN+LTD++++++++++++++For%3A+Mar+02/26086764.html Mon, 02 Mar 2026 07:00:00 -0500 CGEN O.00653212 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++COMPUGEN+LTD++++++++++++++For%3A+Mar+02/26086764.html si-local-file:///var/storage/secattach/20260302/26086764.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++COMPUGEN+LTD++++++++++++++For%3A+Mar+02/26086764.html Mon, 02 Mar 2026 07:00:00 -0500 CGEN O.00653212 http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+Upcoming+Investor+Conferences/26025746.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>Feb. 19, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that management will participate in the following upcoming investor conferences:</p> <p><b>Oppenheimer 36th Annual <span>Healthcare Life Sciences Conference</span><br /></b><b>Date:</b> <chron>Thursday, February 26, 2026</chron><br /><b>Location:</b> Virtual<br /><b>Format:</b> Fireside chat and 1x1 meetings<br /><b>Fireside chat time:</b> <chron>2 PM ET</chron></p><p><b><span value="ACORN:3681754265" idsrc="xmltag.org" >Leerink Partners</span> 2026 Global Healthcare Conference<br /></b><b>Date: </b><chron>Monday, March 9, 2026</chron><br /><b>Location:</b> <location value="LU/us.fl.miami" idsrc="xmltag.org" >Miami, Florida</location>, <location value="LC/us" idsrc="xmltag.org" >U.S.</location><br http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+Upcoming+Investor+Conferences/26025746.html Thu, 19 Feb 2026 07:00:00 -0500 A.08181543 A.36817542 CGEN CGEN O.00653212 O.25213119 O.34295762 http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+Upcoming+Investor+Conferences/26025746.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>Feb. 19, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that management will participate in the following upcoming investor conferences:</p> <p><b>Oppenheimer 36th Annual <span>Healthcare Life Sciences Conference</span><br /></b><b>Date:</b> <chron>Thursday, February 26, 2026</chron><br /><b>Location:</b> Virtual<br /><b>Format:</b> Fireside chat and 1x1 meetings<br /><b>Fireside chat time:</b> <chron>2 PM ET</chron></p><p><b><span value="ACORN:3681754265" idsrc="xmltag.org" >Leerink Partners</span> 2026 Global Healthcare Conference<br /></b><b>Date: </b><chron>Monday, March 9, 2026</chron><br /><b>Location:</b> <location value="LU/us.fl.miami" idsrc="xmltag.org" >Miami, Florida</location>, <location value="LC/us" idsrc="xmltag.org" >U.S.</location><br http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+Upcoming+Investor+Conferences/26025746.html Thu, 19 Feb 2026 07:00:00 -0500 A.08181543 A.36817542 CGEN CGEN O.00653212 O.25213119 O.34295762 http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+Upcoming+Investor+Conferences/26025746.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>Feb. 19, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that management will participate in the following upcoming investor conferences:</p> <p><b>Oppenheimer 36th Annual <span>Healthcare Life Sciences Conference</span><br /></b><b>Date:</b> <chron>Thursday, February 26, 2026</chron><br /><b>Location:</b> Virtual<br /><b>Format:</b> Fireside chat and 1x1 meetings<br /><b>Fireside chat time:</b> <chron>2 PM ET</chron></p><p><b><span value="ACORN:3681754265" idsrc="xmltag.org" >Leerink Partners</span> 2026 Global Healthcare Conference<br /></b><b>Date: </b><chron>Monday, March 9, 2026</chron><br /><b>Location:</b> <location value="LU/us.fl.miami" idsrc="xmltag.org" >Miami, Florida</location>, <location value="LC/us" idsrc="xmltag.org" >U.S.</location><br http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+Upcoming+Investor+Conferences/26025746.html Thu, 19 Feb 2026 07:00:00 -0500 A.08181543 A.36817542 CGEN CGEN O.00653212 O.25213119 O.34295762 http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+Upcoming+Investor+Conferences/26025746.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>Feb. 19, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that management will participate in the following upcoming investor conferences:</p> <p><b>Oppenheimer 36th Annual <span>Healthcare Life Sciences Conference</span><br /></b><b>Date:</b> <chron>Thursday, February 26, 2026</chron><br /><b>Location:</b> Virtual<br /><b>Format:</b> Fireside chat and 1x1 meetings<br /><b>Fireside chat time:</b> <chron>2 PM ET</chron></p><p><b><span value="ACORN:3681754265" idsrc="xmltag.org" >Leerink Partners</span> 2026 Global Healthcare Conference<br /></b><b>Date: </b><chron>Monday, March 9, 2026</chron><br /><b>Location:</b> <location value="LU/us.fl.miami" idsrc="xmltag.org" >Miami, Florida</location>, <location value="LC/us" idsrc="xmltag.org" >U.S.</location><br http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+Upcoming+Investor+Conferences/26025746.html Thu, 19 Feb 2026 07:00:00 -0500 A.08181543 A.36817542 CGEN CGEN O.00653212 O.25213119 O.34295762 http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+Upcoming+Investor+Conferences/26025746.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>Feb. 19, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that management will participate in the following upcoming investor conferences:</p> <p><b>Oppenheimer 36th Annual <span>Healthcare Life Sciences Conference</span><br /></b><b>Date:</b> <chron>Thursday, February 26, 2026</chron><br /><b>Location:</b> Virtual<br /><b>Format:</b> Fireside chat and 1x1 meetings<br /><b>Fireside chat time:</b> <chron>2 PM ET</chron></p><p><b><span value="ACORN:3681754265" idsrc="xmltag.org" >Leerink Partners</span> 2026 Global Healthcare Conference<br /></b><b>Date: </b><chron>Monday, March 9, 2026</chron><br /><b>Location:</b> <location value="LU/us.fl.miami" idsrc="xmltag.org" >Miami, Florida</location>, <location value="LC/us" idsrc="xmltag.org" >U.S.</location><br http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+Upcoming+Investor+Conferences/26025746.html Thu, 19 Feb 2026 07:00:00 -0500 A.08181543 A.36817542 CGEN CGEN O.00653212 O.25213119 O.34295762 http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+Upcoming+Investor+Conferences/26025746.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..holon" idsrc="xmltag.org" >HOLON, Israel</location></span>, <span class="legendSpanClass"><chron>Feb. 19, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.cgen.com/" target="_blank" rel="nofollow"><span value="TelAviv:CGEN" idsrc="xmltag.org" >Compugen Ltd.</span></a> (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that management will participate in the following upcoming investor conferences:</p> <p><b>Oppenheimer 36th Annual <span>Healthcare Life Sciences Conference</span><br /></b><b>Date:</b> <chron>Thursday, February 26, 2026</chron><br /><b>Location:</b> Virtual<br /><b>Format:</b> Fireside chat and 1x1 meetings<br /><b>Fireside chat time:</b> <chron>2 PM ET</chron></p><p><b><span value="ACORN:3681754265" idsrc="xmltag.org" >Leerink Partners</span> 2026 Global Healthcare Conference<br /></b><b>Date: </b><chron>Monday, March 9, 2026</chron><br /><b>Location:</b> <location value="LU/us.fl.miami" idsrc="xmltag.org" >Miami, Florida</location>, <location value="LC/us" idsrc="xmltag.org" >U.S.</location><br http://www.streetinsider.com/Press+Releases/Compugen+to+Participate+in+Upcoming+Investor+Conferences/26025746.html Thu, 19 Feb 2026 07:00:00 -0500 A.08181543 A.36817542 CGEN CGEN O.00653212 O.25213119 O.34295762